A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China-Reference-Cited by-同舟云学术

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China

Published:2022-01 Issue:1 Volume:17 Page:1-13
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Tu Hai-Yan,Feng Jifeng,Shi Meiqi,Zhao Jun,Wang Yuyan,Chang Jianhua,Wang Jialei,Cheng Ying,Zhu Jing,Tan Eng-Huat,Li Kai,Zhang Yiping,Lee Victor,Yang Cheng-Ta,Su Wu-Chou,Lam David Chi-Leung,Srinivasa B. J.,Rajappa Senthil,Ho Ching-Liang,Lam Kwok Chi,Hu Yi,Bondarde Shailesh Arjun,Liu Xiaoqing,Tian Yahui,Xue Zhiyi,Cseh Agnieszka,Huang Dennis Chin-Lun,Zhou Caicun,Wu Yi-Long^ORCID

Funder

Boehringer Ingelheim Inc

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-021-00859-6.pdf

Reference41 articles.

1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. https://doi.org/10.1056/NEJMoa0810699.

2. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. https://doi.org/10.1016/S1470-2045(11)70393-X.

3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8. https://doi.org/10.1056/NEJMoa0909530.